Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report

H. Tanino, S. Miyoshi, T. Furukawa, T. Bessho, S. Maebeya, T. Suzuma, I. Hirai, J. Arimoto, N. Harada, T. Hoso, Y. Naito

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Histoculture drug response assay (HDRA) was applied to a biopsy specimen of advanced thymic cancer from a 68-years-old male patient. HDRA revealed that the tumor was not sensitive to CDDP but highly sensitive to 5-FU, ADM and MMC, which were administered as induction chemotherapy. The tumor regressed to 14 % of the pretreatment size and was able to be completely resected with right and left brachiocephalic veins, superior vena cava, pericardium, right phrenic nerve and a part of right lung. Histologically, only a few small cancer nests remained in the fibrous tissue. The patient is alive and disease free 32 months after surgery. This result suggests that HDRA is useful to select anticancer agents which are sensitive to a rare kind of carcinoma such as thymic cancer.

Original languageEnglish
Pages (from-to)861-864
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume24
Issue number7
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Thymus Neoplasms
Induction Chemotherapy
Brachiocephalic Veins
Pharmaceutical Preparations
Neoplasms
Phrenic Nerve
Superior Vena Cava
Pericardium
Fluorouracil
Antineoplastic Agents
Carcinoma
Biopsy
Lung

Keywords

  • Chemosensitivity test
  • Histoculture drug response assay
  • Thymic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Tanino, H., Miyoshi, S., Furukawa, T., Bessho, T., Maebeya, S., Suzuma, T., ... Naito, Y. (1997). Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report. Gan to kagaku ryoho. Cancer & chemotherapy, 24(7), 861-864.

Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report. / Tanino, H.; Miyoshi, S.; Furukawa, T.; Bessho, T.; Maebeya, S.; Suzuma, T.; Hirai, I.; Arimoto, J.; Harada, N.; Hoso, T.; Naito, Y.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 24, No. 7, 1997, p. 861-864.

Research output: Contribution to journalArticle

Tanino, H, Miyoshi, S, Furukawa, T, Bessho, T, Maebeya, S, Suzuma, T, Hirai, I, Arimoto, J, Harada, N, Hoso, T & Naito, Y 1997, 'Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 24, no. 7, pp. 861-864.
Tanino, H. ; Miyoshi, S. ; Furukawa, T. ; Bessho, T. ; Maebeya, S. ; Suzuma, T. ; Hirai, I. ; Arimoto, J. ; Harada, N. ; Hoso, T. ; Naito, Y. / Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report. In: Gan to kagaku ryoho. Cancer & chemotherapy. 1997 ; Vol. 24, No. 7. pp. 861-864.
@article{f436db03ebd4422aba4ad9aedc1cb45b,
title = "Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report",
abstract = "Histoculture drug response assay (HDRA) was applied to a biopsy specimen of advanced thymic cancer from a 68-years-old male patient. HDRA revealed that the tumor was not sensitive to CDDP but highly sensitive to 5-FU, ADM and MMC, which were administered as induction chemotherapy. The tumor regressed to 14 {\%} of the pretreatment size and was able to be completely resected with right and left brachiocephalic veins, superior vena cava, pericardium, right phrenic nerve and a part of right lung. Histologically, only a few small cancer nests remained in the fibrous tissue. The patient is alive and disease free 32 months after surgery. This result suggests that HDRA is useful to select anticancer agents which are sensitive to a rare kind of carcinoma such as thymic cancer.",
keywords = "Chemosensitivity test, Histoculture drug response assay, Thymic cancer",
author = "H. Tanino and S. Miyoshi and T. Furukawa and T. Bessho and S. Maebeya and T. Suzuma and I. Hirai and J. Arimoto and N. Harada and T. Hoso and Y. Naito",
year = "1997",
language = "English",
volume = "24",
pages = "861--864",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer - A case report

AU - Tanino, H.

AU - Miyoshi, S.

AU - Furukawa, T.

AU - Bessho, T.

AU - Maebeya, S.

AU - Suzuma, T.

AU - Hirai, I.

AU - Arimoto, J.

AU - Harada, N.

AU - Hoso, T.

AU - Naito, Y.

PY - 1997

Y1 - 1997

N2 - Histoculture drug response assay (HDRA) was applied to a biopsy specimen of advanced thymic cancer from a 68-years-old male patient. HDRA revealed that the tumor was not sensitive to CDDP but highly sensitive to 5-FU, ADM and MMC, which were administered as induction chemotherapy. The tumor regressed to 14 % of the pretreatment size and was able to be completely resected with right and left brachiocephalic veins, superior vena cava, pericardium, right phrenic nerve and a part of right lung. Histologically, only a few small cancer nests remained in the fibrous tissue. The patient is alive and disease free 32 months after surgery. This result suggests that HDRA is useful to select anticancer agents which are sensitive to a rare kind of carcinoma such as thymic cancer.

AB - Histoculture drug response assay (HDRA) was applied to a biopsy specimen of advanced thymic cancer from a 68-years-old male patient. HDRA revealed that the tumor was not sensitive to CDDP but highly sensitive to 5-FU, ADM and MMC, which were administered as induction chemotherapy. The tumor regressed to 14 % of the pretreatment size and was able to be completely resected with right and left brachiocephalic veins, superior vena cava, pericardium, right phrenic nerve and a part of right lung. Histologically, only a few small cancer nests remained in the fibrous tissue. The patient is alive and disease free 32 months after surgery. This result suggests that HDRA is useful to select anticancer agents which are sensitive to a rare kind of carcinoma such as thymic cancer.

KW - Chemosensitivity test

KW - Histoculture drug response assay

KW - Thymic cancer

UR - http://www.scopus.com/inward/record.url?scp=0030967711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030967711&partnerID=8YFLogxK

M3 - Article

C2 - 9170526

AN - SCOPUS:0030967711

VL - 24

SP - 861

EP - 864

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -